Table 2.

Univariate analysis of prognostic factors in progression-free survival

Adverse events	Median (months)	95% C.I. of median	P value	Hazard ratio	95% C.I. of HR	P value
Skin			.274
Grade 0 (n = 32)	2.8	1.9–3.8		1
Grade 1–2 (n = 17)	3.6	1.6–5.6		0.71	0.38–1.32	.278
Skin/vitiligo			.092
Grade 0 (n = 30)	2.5	1.6–3.4		1
Grade 1–2 (n = 19)	4.6	2.5–6.7		0.59	0.32–1.10	.096
Mucositis			.287
Grade 0 (n = 46)	3.1	2.5–3.8		1
Grade 1–2 (n = 3)	3.0	0.4–5.6		1.90	0.57–6.29	.296
Colitis			.624
Grade 0 (n = 43)	3.2	2.6–3.7		1
Grade 1–2 (n = 6)	3.0	2.3–3.7		1.24	0.52–2.96	.626
Liver			.353
Grade 0 (n = 47)	3.2	2.7–3.6		1
Grade 1–2 (n = 1)	3.1	–		1.48	0.20–10.99	.700
Grade 3–5 (n = 1)	2.1	–		3.89	0.50–30.19	.194
Lung			.005
Grade 0 (n = 47)	3.2	2.8–3.5		1
Grade 3–5 (n = 2)	0.9	–		6.71	1.44–31.38	.016
Endocrine			.094
Grade 0 (n = 40)	2.7	2.1–3.3		1
Grade 1–2 (n = 9)	6.1	2.7–9.6		0.52	0.24–1.13	.100
Fatigue			.024
Grade 0 (n = 42)	3.2	2.7–3.7		1
Grade 1–2 (n = 7)	2.4	1.5–3.4		2.56	1.09–6.00	.030
Vitiligo			.234
Grade 0 (n = 47)	3.0	2.5–3.4		1
Grade 1–2 (n = 2)	4.7	–		0.32	0.04–2.33	.261
Skin/vitiligo/endocrine			.003
Grade 0 (n = 26)	2.3	1.7–2.8		1
Any grade (n = 23)	4.8	4.3–5.3		0.40	0.21–0.74	.003
Overall			.001
Grade 0 (n = 19)	2.5	1.7–3.3		1
Grade 1–2 (n = 27)	4.6	2.8–6.4		0.52	0.27–0.98	.042
Grade 3–5 (n = 3)	2.0	0.2–3.8		4.24	1.1–16.3	.035

C.I. confidence interval